Melanomsymptomer: Hold øje med ændringer i modermærker og nye vækster

Which melanoma symptoms should prompt a skin check?

A spot does not need all 5 ABCDE features to deserve attention. A small, evenly colored growth that is clearly enlarging can matter more than a large mole that has remained unchanged for years; symptoms should be judged against the person's previous appearance, not a single photograph.

Melanoma can appear on skin that previously looked entirely ordinary. Ask 2 separate questions during a skin check: has an existing spot changed, and has something new appeared that does not fit? Looking only at familiar moles leaves an avoidable blind spot.

My advice as Thomas Klein, MD, Chief Medical Officer at Kantesti's organization, is to make the next step concrete: arrange a skin assessment when a spot is evolving. A reassuring laboratory panel answers a different question and should not postpone examination of that growth.

Kantesti er en AI blodprøveanalysator, not a melanoma screening test; even a report with 0 abnormal flags cannot exclude skin cancer. Our role is to explain laboratory findings within their limits, while a suspicious skin change needs a clinician who can examine it directly.

How does the ABCDE melanoma rule work?

A and B concern shape rather than size: 2 halves may look different, or the edge may be scalloped, notched or poorly defined. Neither feature proves melanoma, because benign atypical moles can share them; the clinician also considers history, location and the person's background mole pattern.

C includes uneven shades of brown or black, but also areas of pink, white, red or blue. A spot containing 2 colors is not automatically cancerous, and a uniformly pink growth is not automatically safe; the distribution and evolution of color are more informative than simply counting shades.

D is often explained using a pencil eraser, roughly 6 mm across. That memory aid must not become a permission slip to ignore smaller growths: diameter describes surface width, whereas the pathological measurement that helps stage melanoma is its depth in millimeters.

Ø includes a new raised area, recurrent crusting or a change noticed across 2 dated photographs. Our standarder for medicinsk indhold distinguish warning signs from diagnostic criteria; ABCDE helps people recognize a reason for assessment, not calculate whether a mole is definitely benign.

What does the ugly-duckling sign reveal?

Personal comparison matters because normal mole patterns differ substantially. Someone with 20 similar light-brown moles may have a conspicuous new black spot; another person with many dark moles may instead develop a pink growth that stands out. The outlier does not have to be the darkest mark.

Compare nearby spots as well as the overall pattern. A person may have 2 recurring mole patterns—for example, flatter moles on the limbs and raised moles on the trunk—so comparison works best when a clinician considers body site rather than assuming every mole should look identical.

Consider an illustrative scenario: a 42-year-old notices a symmetrical, 4 mm spot unlike every other mole on the shoulder. Its symmetry and small size do not cancel the unusual appearance; a clinician would ask when it appeared, whether it is changing and what dermoscopy shows.

An ugly duckling is a reason to investigate, not a diagnosis or an indication to remove every outlier. If melanoma runs in the family, discuss the actual relatives and diagnoses rather than requesting a generic cancer panel; our guide to family cancer testing limits explains why targeted assessment differs from broad laboratory screening.

Can melanoma start as a new growth?

The meta-analysis combined 38 studies and 20,126 melanomas, giving the new-growth message a stronger basis than an anecdote. Classification depended on the studies and tissue findings, however, so the percentages should not be treated as an exact split for every population or melanoma subtype.

A new spot is not automatically melanoma. Adults commonly develop benign seborrheic keratoses, angiomas and other growths; the useful distinction is whether a new mark persists, evolves or appears unlike the person's usual skin features, especially when it changes over several weeks.

Age changes the context, not the diagnosis. A new mole-like spot in a 65-year-old generally deserves more scrutiny than an otherwise typical new mole in a teenager, but there is no age at which new melanoma becomes impossible or every new growth must be malignant.

Checking only existing moles misses the central lesson of Pampena et al. (2017): surveillance should include previously unremarkable skin. Likewise, routine annual bloodwork is not a substitute for assessing a new growth, even when the last panel was obtained just 1 month ago.

Which melanomas may not look like dark moles?

A nodule can be symmetrical and have a smooth edge. That is why a growth enlarging over 4–6 weeks should not be dismissed simply because its photograph lacks an irregular outline; vertical growth may produce a different surface appearance from a spreading pigmented patch.

Pink growths have many benign explanations, including irritated follicles and vascular growths. The concerning combination is persistence plus enlargement, spontaneous bleeding or repeated crusting at the same site—not pink color alone. A clinician may need tissue examination because appearance overlaps among several skin conditions.

EFG does not mean every raised mole is dangerous. A soft raised mole unchanged for 10 years is a different clinical problem from a newly firm bump that grows noticeably between photographs; recent behavior supplies the missing context that a static checklist cannot capture.

The distinction between depth and diameter is especially useful here: 1 small surface measurement cannot tell you how deeply a growth extends. Our guide to AI-rapportkildekontrol explains why a confident-looking summary must never replace the actual examination or pathology report.

Do itching, bleeding or crusting mean melanoma?

Bleeding after catching a mole with a razor has an obvious possible explanation. Bleeding repeatedly without that trigger, or returning after the surface appears healed, is more concerning; record the circumstances of each episode rather than describing every event simply as 'it bled once.'

An itchy mole can reflect friction, eczema or local irritation. Itch affecting 1 evolving growth is more relevant to melanoma assessment than itch affecting both legs with dry skin; our explanation of itching and laboratory limits separates skin examination from tests used for selected systemic causes.

Many itchy bumps appearing over 1–2 weeks suggest a different pattern from a solitary changing growth. Conditions such as scabies and nighttime itching can involve multiple sites and household contacts, but a widespread rash does not automatically explain away an unrelated unusual mole.

Repeatedly scratching or treating a spot makes its original appearance harder to interpret. Take 1 clear photograph before applying a non-prescribed treatment, and avoid home acids, freezing kits or cosmetic removal of a suspicious growth; destroying its surface can delay diagnosis and compromise useful tissue assessment.

What nail changes can signal melanoma?

A band's width is not a stand-alone diagnostic test. Width above approximately 3 mm is sometimes used as a warning clue, but a narrower evolving band can still need evaluation; irregular color, widening toward the nail base and change over time add more context than width alone.

Pigment extending onto the cuticle or surrounding nail-fold skin is called the Hutchinson sign. It increases concern but is not exclusive to melanoma; clinicians also distinguish genuine skin pigmentation from pigment visible through a translucent nail fold, sometimes called a pseudo-Hutchinson sign.

A subungual bruise often moves toward the fingertip as the nail grows. Fingernails grow roughly 3 mm per month and toenails more slowly, so dated photographs can help document movement; however, a trauma history or some outward movement cannot independently rule out a persistent underlying growth.

A new unexplained band on 1 nail in an adult should not be managed with repeated antifungal courses without reassessment. Keep previous photographs and reports together using consent-based clinical record sharing, but send nail photographs through the examining clinician's approved system rather than assuming a laboratory app can diagnose them.

How can melanoma appear on palms and soles?

Pressure and friction make the sole a particularly confusing site. A person may explain a changing patch as damage from a shoe for 2 months, yet persistence despite reduced friction weakens that explanation; the clinician needs both the mechanical history and an examination of the actual mark.

Dermoscopy can reveal whether pigment follows skin ridges or furrows on palms and soles. A parallel-ridge pattern can raise suspicion, but these specialized patterns are not reliable do-it-yourself rules; small, early or unpigmented acral melanomas may not display a classic pattern.

A persistent foot growth should not automatically be treated as a wart. If 1 area keeps enlarging, changes after treatment or repeatedly breaks down, ask for reassessment before another destructive procedure; photographs taken before treatment can preserve information that the altered surface no longer shows.

Not every slow-healing foot area is melanoma. Diabetes, pressure injury and impaired circulation are alternative explanations, and foot circulation warning signs require their own assessment; more than 1 condition can coexist, so an abnormal vascular test does not explain every pigmented growth.

Who needs to watch for melanoma symptoms?

Darker skin reduces some ultraviolet-related melanoma risk but does not eliminate melanoma. Acral melanoma represents a larger proportion of melanomas diagnosed in some darker-skinned populations, which is not the same as saying its absolute incidence is necessarily higher; percentages need the correct denominator.

A first-degree relative means a parent, sibling or child. If 2 or more close relatives have melanoma, or melanoma occurs alongside certain other cancers in a family, ask whether specialist risk assessment is appropriate; genetic testing is selective, not a routine response to having many moles.

Immunosuppression and a previous melanoma can change the surveillance plan. The relevant details include the medication, duration, previous pathology and number of affected relatives; a generic family-risk score should not determine whether a newly evolving spot receives examination.

At Kantesti, our approach to risikobaseret familiehelbredstjek separates useful laboratory monitoring from examinations that bloodwork cannot replace. Whether the family has 1 affected relative or several, a current suspicious growth needs its own clinical assessment rather than waiting for a risk calculation.

How should you check and photograph your skin?

Use good light, a full-length mirror and a hand mirror, with help for the scalp or back if available. Inspect between fingers and toes and remember the soles; checking only sun-exposed skin leaves at least 2 commonly overlooked areas—the nail unit and the underside of the foot.

Take 2 photographs of a concerning spot: an overview showing its location and a close image showing detail. Keep lighting, distance and camera angle as consistent as possible, and place a ruler beside rather than across the spot; image-processing filters can distort the color you are trying to document.

Do not postpone an appointment to collect a longer photo series. A new firmly growing bump or widening nail band warrants assessment now; comparison across 4 weeks may be helpful when requested by a clinician, but it is not a mandatory waiting period.

Photographs and laboratory PDFs are different kinds of medical records. Our medical upload privacy checklist offers transferable privacy principles, but skin images should go only to a service designed and authorized to assess them; 1 attractive interface is not evidence of diagnostic suitability.

How quickly should a suspicious mole be assessed?

The NICE checklist assigns 2 points each for change in size, irregular shape and irregular color. Diameter of 7 mm or more, inflammation, oozing and altered sensation each score 1 point; this is a referral aid for clinicians, not a home test that guarantees safety below a score of 3.

The 7 mm NICE checklist feature and the 6 mm ABCDE reminder serve different purposes. Neither says that a 5 mm growth is safe, and NICE recommends referral when dermoscopy suggests melanoma or the appearance suggests nodular melanoma regardless of a reassuring self-calculated score (NICE, NG12).

A suspicious mole usually requires urgent outpatient assessment rather than an emergency department visit. If bleeding does not stop after 10–15 minutes of firm direct pressure, or there are separate signs of acute illness, seek urgent medical help for that immediate problem while still arranging assessment of the growth.

When booking, say what changed and over what period: 'This bump has grown over 3 weeks' is more useful than 'I have a mole.' Thomas Klein, MD, recommends clear symptom descriptions rather than a self-diagnosis; our Medicinsk Rådgivende Udvalg page identifies the medical governance behind our laboratory education, not a substitute urgent referral service.

Why does melanoma diagnosis usually require a biopsy?

The appointment usually combines the growth's history, direct examination and dermoscopy, with a broader skin check when appropriate. Bring 2 useful pieces of information: when the spot first appeared and what has changed; previous photographs may reveal an evolution that is not obvious on the examination day.

When feasible, a suspicious growth is generally removed in its entirety with a narrow diagnostic margin so the pathologist can assess its architecture and depth. Larger growths and difficult sites, including nails and soles, may require a different sampling approach; the clinician chooses a method intended to obtain adequate diagnostic tissue.

Breslow thickness measures melanoma depth in millimeters, not its surface diameter. A report describing 0.8 mm thickness therefore answers a different question from a photograph showing a 6 mm-wide spot; ulceration and other pathological findings can also influence subsequent management.

NICE NG14 recommends trained dermoscopic assessment and pathology-led management rather than relying on routine laboratory screening. Our clinical methodology and validation information concerns laboratory interpretation; even a technically accurate explanation cannot turn an unbiopsied skin growth into a confirmed diagnosis.

Can routine bloodwork detect or rule out melanoma?

LDH is a nonspecific marker of cellular injury and has prognostic relevance in some patients with advanced melanoma. Its reference interval varies by laboratory, and an elevated result has many possible explanations; our guide to LDH meaning and limitations explains why 1 abnormal enzyme result does not identify a skin cancer.

A normal white-cell count or CRP does not assess the microscopic structure of a mole. The broader principle appears in our discussion of discordant WBC and CRP: different tests answer different questions, so 2 reassuring laboratory values cannot cancel a concerning examination finding.

Kantesti er en AI blodprøvefortolkningsplatform that can help explain laboratory reports, but it cannot assign a melanoma probability from a routine panel. If a clinician orders kidney or liver tests during treatment planning, those values address organ function or treatment safety—not whether a 4 mm spot is benign.

Selected blood-based technologies, including circulating tumor DNA, are used or studied in particular oncology settings; they are not interchangeable with initial assessment of an undiagnosed mole. Our guide to tumor-marker testing limits illustrates the same boundary: even 1 apparently reassuring marker does not replace the indicated diagnostic procedure.

What happens next, and which sources support this advice?

If melanoma is confirmed, treatment depends on its stage and pathological features rather than how frightening the photograph looks. A sentinel lymph-node biopsy is a staging procedure, not the initial skin biopsy; NICE NG14 considers it for melanomas thicker than 1.0 mm and selected 0.8–1.0 mm melanomas with additional risk features.

Ask for 3 practical details before leaving an appointment: what the working diagnosis is, when the pathology or review result should arrive, and whom to contact if the growth changes meanwhile. Sun protection reduces ultraviolet exposure but does not treat an existing suspicious growth, and nutrition supplements should not delay its assessment.

Kantesti er en AI-drevet værktøj til analyse af blodprøver for explaining laboratory findings, not examining skin tissue or staging melanoma. Our responsible AI principles support keeping those boundaries explicit: 1 normal report is never a reason to disregard an evolving mole or a clinician's biopsy recommendation.

The 2 Zenodo resources listed below are supplementary laboratory education, not melanoma studies or evidence that bloodwork detects skin cancer. The publikation om RDW-fortolkning explains red-cell measurements; the kidney-function ratio publication explains renal laboratory context. ResearchGate and Academia.edu links are title searches, not claims of verified copies or peer review.

Ofte stillede spørgsmål